Suppression of immunoglobulin production by a novel dihydroorotate dehydrogenase inhibitor, S-2678.
@article{Deguchi2008SuppressionOI, title={Suppression of immunoglobulin production by a novel dihydroorotate dehydrogenase inhibitor, S-2678.}, author={Masashi Deguchi and J. Kishino and M. Hattori and Y. Furue and M. Yamamoto and Izumi Mochizuki and Motofumi Iguchi and Y. Hirano and Kanji Hojou and M. Nagira and Y. Nishitani and Ken-ichi Okazaki and K. Yasui and A. Arimura}, journal={European journal of pharmacology}, year={2008}, volume={601 1-3}, pages={ 163-70 } }
We discovered a novel dihydroorotate dehydrogenase (DHO-DH) inhibitor, S-2678 ([2-fluoro-2',5'-dimethyl-4'-[6-(3-methyl-2-butenyloxy) pyridin-3-yl] biphenyl-4-yl]-(3-methyl-2-butenyl) amine). Its inhibitory activity against DHO-DH was more potent than that of A77 1726, an active metabolite of the anti-rheumatic drug leflunomide. S-2678 suppressed immunoglobulin production in mouse B cells and human peripheral blood mononuclear cells in vitro, with little or no inhibition of cell proliferation… CONTINUE READING
Figures, Tables, and Topics from this paper
5 Citations
Plasmodium dihydroorotate dehydrogenase: a promising target for novel anti-malarial chemotherapy.
- Biology, Medicine
- Infectious disorders drug targets
- 2010
- 137
Systems pharmacology uncovers Janus functions of botanical drugs: activation of host defense system and inhibition of influenza virus replication
- Biology, Medicine
- Integrative biology : quantitative biosciences from nano to macro
- 2013
- 52
- PDF
Discovery of novel inhibitors for DHODH via virtual screening and X-ray crystallographic structures.
- Chemistry, Medicine
- Bioorganic & medicinal chemistry letters
- 2010
- 13
References
SHOWING 1-10 OF 22 REFERENCES
Purification of human dihydro-orotate dehydrogenase and its inhibition by A77 1726, the active metabolite of leflunomide.
- Biology, Medicine
- The Biochemical journal
- 1998
- 113
- Highly Influential
Dihydroorotate Dehydrogenase Is a High Affinity Binding Protein for A77 1726 and Mediator of a Range of Biological Effects of the Immunomodulatory Compound (*)
- Biology, Medicine
- The Journal of Biological Chemistry
- 1995
- 193
- PDF
Leflunomide Inhibits Pyrimidine de Novo Synthesis in Mitogen-stimulated T-lymphocytes from Healthy Humans*
- Chemistry, Medicine
- The Journal of Biological Chemistry
- 1998
- 225
- PDF
In vitro and in vivo antitumor activity of a novel immunomodulatory drug, leflunomide: mechanisms of action.
- Biology, Chemistry
- Biochemical pharmacology
- 1999
- 71
The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis.
- Chemistry, Medicine
- The Journal of pharmacology and experimental therapeutics
- 1995
- 200
Inhibition of JAK3 and STAT6 tyrosine phosphorylation by the immunosuppressive drug leflunomide leads to a block in IgG1 production.
- Biology, Medicine
- Journal of immunology
- 1998
- 165
Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-kappa B activation and gene expression.
- Chemistry, Medicine
- Journal of immunology
- 1999
- 222
Regulation of B cell function by the immunosuppressive agent leflunomide.
- Biology, Medicine
- Transplantation
- 1996
- 156
Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases.
- Medicine, Chemistry
- Immunopharmacology
- 2000
- 206
Discovery of activation-induced cytidine deaminase, the engraver of antibody memory.
- Biology, Medicine
- Advances in immunology
- 2007
- 112